REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2012

Sep 20, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-09-18

Reporting Person: Powchik Peter (SVP Clinical Development & Reg)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-09-18	Common Stock	M	15000.0	$16.8	Acquired	45134.0	Direct
2012-09-18	Common Stock	F	1693.0	$148.78	Disposed	43441.0	Direct
2012-09-18	Common Stock	F	6130.0	$148.78	Disposed	37311.0	Direct
2012-09-19	Common Stock	S	2977.0	$146.89	Disposed	34334.0	Direct
2012-09-19	Common Stock	S	3200.0	$147.16	Disposed	31134.0	Direct
2012-09-19	Common Stock	S	1000.0	$148.0	Disposed	30134.0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-09-18	Non-Qualified Stock Option (right to buy)	$16.8	M	15000.0	Disposed	2018-12-17	Common Stock (15000.0)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1532.0	Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: Represents volume-weighted average price of sales of 2,977 shares of Company stock on September 19, 2012 at prices ranging from $146.80 to $146.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 19, 2012 at each separate price.

F3: Represents volume-weighted average price of sales of 3,200 shares of Company stock on September 19, 2012 at prices ranging from $147.01 to $147.25. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 19, 2012 at each separate price.

F4: On December 17, 2008, the reporting person was granted an option to purchase 30,000 shares of Common Stock. The option was eligible to vest, partially or in full, on December 31, 2011, based on the extent to which the company satisfied certain performance criteria. The performance criteria were met and the option vested as to all shares.

F5: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.